Merck's Calderasib + Keytruda Combo Gets FDA Breakthrough Designation for KRAS G12C NSCLC
MRK sits 59% above its 52-week low of $75.4.
Summary
Merck's investigational drug calderasib, combined with Keytruda, received FDA Breakthrough Therapy Designation for first-line treatment of advanced KRAS G12C-mutant non-small cell lung cancer. This designation accelerates the development and review process, indicating the FDA's view that the therapy could offer substantial improvement for a significant patient population. The news strengthens Merck's oncology pipeline and future growth prospects, building on recent positive trial results and strong Q1 earnings.
At the time of this announcement, MRK was trading at $120.22 on NYSE in the Life Sciences sector, with a market capitalization of approximately $296.1B. The 52-week trading range was $75.40 to $125.14. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.